LL-37 Antimicrobial Peptide: Mechanisms of Action and Therapeutic Potential Against Drug-Resistant Pathogens
Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI
Antimicrobial Agents and Chemotherapy · Vol. 57(6) · pp. 2512–2521 · 2013
Comprehensive characterization of LL-37's antimicrobial mechanisms against drug-resistant pathogens including MRSA, Pseudomonas aeruginosa, and Candida species. Demonstrates membrane disruption, biofilm inhibition, and synergy with conventional antibiotics.
Key Findings
LL-37 kills MRSA, P. aeruginosa, and Candida via membrane disruption at MIC of 1–4 μg/mL
Disrupts established biofilms of drug-resistant organisms at sub-MIC concentrations
Synergistic killing with conventional antibiotics at reduced doses
Neutralizes LPS endotoxin, preventing septic shock in animal models
Retains activity against antibiotic-resistant strains that have lost susceptibility to conventional drugs
Methodology
Minimum inhibitory concentration (MIC) assays, time-kill kinetics, biofilm disruption assays, and electron microscopy of membrane disruption. In vivo mouse infection models.
Limitations
In vitro potency may not translate directly to in vivo efficacy due to serum protein binding and protease degradation. Systemic toxicity at high doses limits therapeutic window.
Protocols Using This Research
Tags
Educational use only. Research summaries are provided for informational purposes. Always consult the original publication and a qualified healthcare provider before making clinical decisions.
Related Research
Build a protocol around this research
Our AI Advisor incorporates the latest research to build a personalized peptide protocol for your goals.
Start Assessment